Share-based Payment Arrangement [Abstract] Summary of Stock Option Activity for Amended 2014 Plan and Related Information Share-based Payment Arrangement, Option, Activity [Table Text Block] Summary of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Assumptions Used in Black-Scholes Option-Pricing Model for Stock Options Granted to Employees and Directors Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition, Acquiree [Domain] Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common stock Common Stock [Member] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Project [Axis] Project [Axis] Project [Domain] Project [Domain] Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Signing of Development and Option Agreement Upon Signing Of Development And Option Agreement [Member] Upon Signing Of Development And Option Agreement [Member] Upon Completion of Fifty Percent Development Not Later Than Six Months Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Completion Of Fifty Percent Development Not Later Than Six Months [Member] Upon Delivery of Six Month Batch Development Not Later Than Eleven Months Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Upon Delivery Of Six Month Batch Development Not Later Than Eleven Months [Member] Range Statistical Measurement [Axis] Range Statistical Measurement [Domain] Maximum Maximum [Member] Minimum Minimum [Member] Related Party Related Party [Axis] Related Party Related Party [Domain] MilanaPharm MilanaPharm [Member] MilanaPharm [Member] Hammock Pharmaceuticals, Inc Hammock Pharmaceuticals, Inc. [Member] Hammock Pharmaceuticals, Inc. [Member] Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company Strategic Science And Technologies D Limited Liability Company And Strategic Science Technologies Limited Liability Company [Member] Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC. Orbis Orbis [Member] Orbis [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Licensing Agreements Licensing Agreements [Member] Bayer Healthcare License Agreement Bayer Healthcare License Agreement [Member] Bayer Healthcare License Agreement [Member] Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Development and Option Agreement Development And Option Agreement [Member] Development And Option Agreement [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] License fee License Fee License Fee License fee to be paid upon contingency License Fee, To Be Paid Upon Contingency License Fee, To Be Paid Upon Contingency Milestone payments, contingent amount Milestone Payments Contingent Amount Milestone payments, contingent amount. License agreement termination periodic discontinued sale of product License Agreement Termination Periodic Discontinued Sale Of Product License Agreement Termination Periodic Discontinued Sale Of Product License agreement termination period due to performance failure License Agreement Termination Period Due To Performance Failure License agreement, termination period due to performance failure. License agreement, notice period of termination License Agreement Notice Period Of Termination License Agreement Notice Period Of Termination Milestone payments Research And Development Milestone Payment Research and development milestone payment. Percentage of royalty rate Percentage Of Royalty Rate Percentage of royalty rate. Percentage of rights to inventions by employees under license agreement Percentage Of Rights To Inventions By Employees Under License Agreement Percentage of rights to inventions by employees under license agreement. Upfront license fee paid Upfront License Fee Paid Upfront License Fee Paid Revenue from grant for notice of award Revenue from Contract with Customer, Excluding Assessed Tax Potential annual license maintenance fee, payments in year one Potential Annual License Maintenance Fee, Payments In Year One Potential Annual License Maintenance Fee, Payments In Year One Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Common stock issued to microchips capital stock holders (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Contingent consideration Asset Acquisition, Contingent Consideration Asset Acquisition, Contingent Consideration Commencement period for stage two upon achievement of stage one Commencement Period For Stage Two Upon Achievement Of Stage One Commencement Period For Stage Two Upon Achievement Of Stage One Leases [Abstract] Leased Properties Lessee, Operating Leases [Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Receivables [Abstract] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Grant Grant [Member] Health Care Trust Fund Health Care Trust Fund [Axis] Health Care Trust Fund, Name Health Care Trust Fund, Name [Domain] Eunice Kennedy Shriver National Institute of Child Health and Human Development Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Eunice Kennedy Shriver National Institute Of Child Health And Human Development [Member] Bill And Melinda Gates Foundation Bill And Melinda Gates Foundation [Member] Bill And Melinda Gates Foundation [Member] National Institutes of Health National Institutes Of Health [Member] National Institutes Of Health [Member] Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Cash received from federal grant Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Deferred grant funding Deferred Grant Funding Current Deferred Grant Funding Current Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other receivables Other Receivables, Net, Current Prepaid expenses Prepaid Expense, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Other non-current assets Other Assets, Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities and Equity [Abstract] Current liabilities Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Current portion of lease liabilities Operating Lease, Liability, Current Total current liabilities Liabilities, Current Deferred license revenue Contract with Customer, Liability, Noncurrent Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Lease liabilities long-term Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 8) Commitments and Contingencies Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value, 5,000,000 shares authorized; None issued and outstanding Preferred Stock, Value, Issued Common stock, $0.0001 par value; 120,000,000 shares authorized; 24,700,553 and 19,683,401 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively Common Stock, Value, Issued Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Number of operating segments Number of Operating Segments Cash and cash equivalents Convertible Debt Cash flow from operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Period of insufficient cash and liquidity requirements Period of Insufficient Cash and Liquidity Requirements Period of Insufficient Cash and Liquidity Requirements Business Combinations [Abstract] Schedule Of Business Combination Reverse Merger [Table] Schedule Of Business Combination Reverse Merger [Table] Schedule of business combination reverse merger. Common stock Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development Expense Research and Development Expense [Member] Business Combination Reverse Merger [Line Items] Business Combination Reverse Merger [Line Items] Business combination reverse merger. Business acquisition transaction value Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Business combination shares issued (in usd per share) Business Acquisition, Share Price Cash and cash equivalents Business Combination Reverse Merger Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Business combination reverse merger recognized identifiable assets acquired and liabilities assumed cash and equivalents. Contingent consideration, liability Business Combination, Contingent Consideration, Liability Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Remainder of 2020 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three Total future minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less: Difference between future minimum lease payments and discounted operating lease liabilities Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total operating lease liabilities Operating Lease, Liability Document And Entity Information [Abstract] Document and entity information. Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Current Reporting Status Entity Current Reporting Status Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity [Abstract] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Acquisitions Business Combination Disclosure [Text Block] Income Statement [Abstract] Operating expenses Operating Expenses [Abstract] General and administrative General and Administrative Expense Research and development Research and Development Expense License fees Total operating expenses Operating Expenses Loss from operations Operating Income (Loss) Other income Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Loss per common share - basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Expected life in years Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeiture rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate Share-based compensation arrangement by Share-based payment award fair value assumptions forfeiture rate. Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted-average fair value of options granted (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments Disclosure [Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Leases Lessee, Leases [Policy Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Organization and Description of the Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure License and Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Current Assets Other Current Assets [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Square footage of office space Net Rentable Area Renewal term of operating lease Lessee, Operating Lease, Renewal Term Incremental borrowing rate Lessee, Operating Lease, Discount Rate Right of use asset Operating Lease, Right-of-Use Asset Operating lease, liability, noncurrent Operating Lease, Liability, Noncurrent Non-cash lease expenses Operating Lease, Cost Cash paid for measurement of operating lease liabilities Operating Lease, Payments Operating lease weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Stock-Based Compensation Share-based Payment Arrangement [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] 2015 Stock Incentive Plan Two Thousand And Fifteen Stock Incentive Plan [Member] Two Thousand And Fifteen Stock Incentive Plan [Member] 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Amended and Restated Two Thousand Fourteen Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Award Type Award Type [Axis] Equity Award Award Type [Domain] Employee Stock Option Share-based Payment Arrangement, Option [Member] Restricted Stock Restricted Stock [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Private Dare Private Dare [Member] Private Dare. Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Stock-based compensation expense Share-based Payment Arrangement, Expense Options to purchase number of outstanding shares of common stock (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Annual percentage increase in outstanding number of common stock Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum Increase in number of shares authorized (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Number of Shares, Period Increase (Decrease) Unamortized stock-based compensation expense Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Amortized weighted average period Weighted Average Amortization Period Weighted Average Amortization Period Stockholders Equity [Table] Stockholders Equity [Table] Stockholders' equity. Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2017-11 Accounting Standards Update 2017-11 [Member] Class of Warrant or Right Class of Warrant or Right [Axis] Class of Warrant or Right Class of Warrant or Right [Domain] Warrants Expiring on February 15, 2023 Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Warrants Expiring On February Fifteen Two Thousand Twenty Three [Member] Sale of Stock Sale of Stock [Axis] Sale of Stock Sale of Stock [Domain] ATM Sales Agreement At The Market Sales Agreement [Member] At The Market Sales Agreement [Member] Public Stock Offering Public Stock Offering [Member] Public Stock Offering [Member] Underwritten Offering Over-Allotment Option [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Stockholders' equity. Aggregate commission rate Percentage Of Aggregate Commission Percentage of aggregate commission. Common stock, shares issued and sold (in shares) Stock Issued During Period, Shares, New Issues Gross proceeds on sale of shares of common stock Gross Proceeds From Issuance Of Common Stock Gross Proceeds From Issuance Of Common Stock Offering expenses Offering Expenses Offering Expenses Public offering price in the offering (in usd per share) Sale of Stock, Price Per Share Underwriters overallotment option to purchase additional shares of common stock and warrants period Underwriters Option To Purchase Additional Shares Of Common Stock Period Underwriters option to purchase additional shares of common stock period. Underwriters option to purchase additional shares (in shares) Underwriters Option To Purchase Additional Shares Underwriters option to purchase additional shares. Gross proceeds from offering of common stock and warrants Gross Proceeds From Offering Of Common Stock And Warrants Gross Proceeds From Offering Of Common Stock And Warrants Proceeds received in public offering, net of underwriting discounts and offering expenses Sale of Stock, Consideration Received on Transaction Warrants exercised (in shares) Number Of Common Stock Warrants Exercised Number of common stock warrants exercised. Estimated fair value of warrants recorded in equity Estimated Fair Value Of Warrants Recorded In Equity Estimated Fair Value Of Warrants Recorded In Equity Warrant, exercise price, decrease Warrant, Exercise Price, Decrease Amount recorded to additional paid in capital as a result of triggered anti-diluted provisions Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Issuance of common stock from the exercise of warrants (in shares) Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Adjustments To Additional Paid In Capital, Common Stock And Warrants Issued, Shares Warrant exercises, gross Proceeds from Warrant Exercises Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Accumulated deficit Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Issuance of common stock (in shares) Issuance of common stock Stock Issued During Period, Value, New Issues Issuance of common stock from the exercise of warrants Adjustments to Additional Paid in Capital, Warrant Issued Stock options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Net loss Foreign currency translation adjustments Ending balance (in shares) Ending balance Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Research and development General and administrative General and Administrative Expense [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Stock options Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding beginning balance (in shares) Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (in shares) Canceled/forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding ending balance (in shares) Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding beginning balance (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Canceled/forfeited (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding ending balance (in usd per share) Exercisable (in usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Warrants Expiring on December 1, 2021 Warrants Expiring On December One Two Thousand Twenty One [Member] Warrants expiring on december one two thousand twenty one. Warrants Expiring on December 6, 2021 Warrants Expiring On December Six Two Thousand Twenty One [Member] Warrants expiring on december six two thousand twenty one. Warrants Expiring on April 4, 2026 Warrants Expiring On April Four Two Thousand Twenty Six [Member] Warrants expiring on april four two thousand twenty six. Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Shares underlying outstanding warrants (in shares) Class of Warrant or Right, Outstanding Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Expiration Date Class Of Warrant Or Rights Warrants Expiration Date Class of warrant or rights warrants expiration date. Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Non-cash adjustments reconciling net loss to operating cash flows: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Stock-based compensation Share-based Payment Arrangement, Noncash Expense Non-cash operating lease cost Non-Cash Lease Expense Non-Cash Lease Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Other receivables Increase (Decrease) in Other Receivables Prepaid expenses Increase (Decrease) in Prepaid Expense Other non-current assets Increase Decrease In Other Non Current Assets And Deferred Charges Increase decrease in other non-current assets and deferred charges. Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses Increase (Decrease) in Accrued Liabilities Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Deferred license revenue Increase (Decrease) in Contract with Customer, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from issuance of common stock Net Proceeds From Issuance Of Common Stock And Warrants Net proceeds from issuance of common stock and warrants. Proceeds from the exercise of common stock warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from issuance of common stock and warrants. Proceeds from the exercise of stock options Proceeds from Issuance or Sale of Equity Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and cash equivalents, end of period Supplemental disclosure of non-cash operating and financing activities: Supplemental Cash Flow Information [Abstract] Operating right-of-use assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] ATM Sales ATM Sales [Member] ATM Sales [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Grants receivable Grants Receivable Loan under Paycheck Protection Program Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Coronavirus Aid, Relief, and Economic Security Act, Loan Proceeds Received Interest rate Debt Instrument, Interest Rate, Stated Percentage Obligation to purchase common stock Purchase Obligation Stock registered for resale (up to) Sale of Stock, Maximum Amount Registered Sale of Stock, Maximum Amount Registered Aggregate net proceeds on sales of shares of common stock Proceeds from Issuance of Common Stock Grant Award Grant Award [Text Block] Grant Award [Text Block]